Patel Sushil 4
4 · Revolution Medicines, Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines Director Sushil Patel Exercises Options, Sells Shares
What Happened
- Sushil Patel, a director of Revolution Medicines (RVMD), exercised options to acquire 2,955 shares at $37.54 each (cost ≈ $110,931) on June 29, 2026, and executed multiple open-market sales that day disposing of 5,580 shares for aggregate proceeds of about $1,048,968. The transactions were reported on a Form 4 filed July 1, 2026.
- The activity is largely sales (routine monetization) following an option exercise; the filing also shows a conversion/derivative entry for 2,955 shares reported with $0 proceeds (documenting the derivative conversion).
Key Details
- Transaction date: June 29, 2026; Form 4 filed July 1, 2026 (timely filing).
- Option exercise: 2,955 shares acquired @ $37.54 each (≈ $110,931).
- Open-market sales: 5,580 shares sold in multiple trades for total proceeds ≈ $1,048,968.
- Sale price range (across multiple lots): approximately $182.93 to $192.64 per share; several lots reported as weighted-average prices per footnotes.
- Shares owned after transaction: not explicitly stated in the provided summary; filing notes holdings include 1,191 restricted stock units (RSUs).
- Notable footnotes: trades were executed pursuant to a 10b5-1 trading plan adopted March 30, 2026; several lots executed in multiple trades with weighted-average pricing reported; one derivative conversion line is marked as fully vested.
- Transaction codes: M = exercise/conversion of derivative; S = open-market sale.
Context
- For options-related activity: the insider exercised options (cash outlay of ~$110.9K) and conducted same-day open-market sales. This pattern is commonly used to cover exercise cost or diversify holdings but the filing itself does not state motivations.
- The trades were executed under an established 10b5-1 plan, which is a pre-set trading arrangement that can indicate the sales were pre-planned rather than opportunistic market timing.
Insider Transaction Report
Form 4
Patel Sushil
Director
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-06-29$37.54/sh+2,955$110,931→ 27,236 total - Sale
Common Stock
[F1][F3][F2]2026-06-29$183.17/sh−300$54,952→ 26,936 total - Sale
Common Stock
[F1][F4][F2]2026-06-29$184.59/sh−900$166,128→ 26,036 total - Sale
Common Stock
[F1][F5][F2]2026-06-29$185.90/sh−1,100$204,489→ 24,936 total - Sale
Common Stock
[F1][F6][F2]2026-06-29$186.92/sh−858$160,374→ 24,078 total - Sale
Common Stock
[F1][F7][F2]2026-06-29$187.83/sh−300$56,348→ 23,778 total - Sale
Common Stock
[F1][F2]2026-06-29$188.57/sh−100$18,857→ 23,678 total - Sale
Common Stock
[F1][F8][F2]2026-06-29$190.54/sh−600$114,327→ 23,078 total - Sale
Common Stock
[F1][F9][F2]2026-06-29$191.87/sh−541$103,800→ 22,537 total - Sale
Common Stock
[F1][F10][F2]2026-06-29$192.61/sh−881$169,693→ 21,656 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F11]2026-06-29−2,955→ 13,000 totalExercise: $37.54Exp: 2034-06-19→ Common Stock (2,955 underlying)
Footnotes (11)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.
- [F10]The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F11]Fully vested.
- [F2]Includes 1,191 restricted stock units.
- [F3]The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F7]The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F8]The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F9]The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Jack Anders, as Attorney-in-fact for Sushil Patel|2026-07-01